Use

Xtalks Announces its Life Science Webinar Calendar for February 2024

Retrieved on: 
Thursday, February 1, 2024

TORONTO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, clinical trials, drug discovery & development, food, fundamental research, laboratory technology, patient recruitment & retention, pharmaceutical, pharma manufacturing & supply chain and pharmaceutical regulation
    TORONTO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!
  • Visit http://www.xtalks.com to see our upcoming webinars:
    February 15 - Case Study: EEG Digital Biomarkers in Neuropsychiatric Clinical Studies
    February 15 - Streamlining IRT in Clinical Trials: Simplify, Optimise, Succeed
    February 22 - Endpoint Protection in Rare Disease Trials: Safeguarding Data Integrity for Reliable Outcomes
    February 22 - Responsibly Advancing the Use of AI in Clinical Trials: Current Landscape, Common Misconceptions and Future Opportunities
    February 5 - Unlocking Superior R&D Results: Mastering the FSP Model
    February 14 - Explore the Missing Links of Beauty, Skin, Hair and Joint Wellness
    February 21 - Metabolic Health Trends: The Future of Balanced Wellness
    February 8 - Optimizing Monoclonal Antibody Production: Temperature and Osmolality's Impact
    February 12 and 13 - Electrostatic Spray Drying: A Drying Alternative for Thermosensitive Products (2-Part Series)
    February 27 - Upstream Bioprocessing: DoE Optimization for CHO Cell Cultures
    February 5 - Trial Recruitment Optimization: 5 Reasons Why the Right People Aren't Joining Your Trials
    February 7 - Viral Vector Manufacturing Success Stories: Onboarding to GMP Production
    February 20 - Warehouse Automation Within the Pharmaceutical Industry: Logistics from Dock to Dock

Copan Colibrí™ Receives Third FDA Clearance, Further Expanding Automated ID/AST Workup Capabilities

Retrieved on: 
Tuesday, January 30, 2024

The automated ID/AST preparation instrument is a key component in Copan's full laboratory automation line that revolutionizes the workflow and efficiency of microbiology labs.

Key Points: 
  • The automated ID/AST preparation instrument is a key component in Copan's full laboratory automation line that revolutionizes the workflow and efficiency of microbiology labs.
  • The Colibrí™ system is a fully automated specimen preparation platform designed to prepare MALDI-TOF ID targets and create bacterial suspensions for Antibiotic Susceptibility Testing (AST).
  • The latest FDA clearance recognizes the ability of the Colibrí™ instrument to seamlessly integrate with the Beckman Coulter MicroScan Walkaway Instruments & Panels for ID/AST.
  • Later that year the Colibri™ system received FDA 510(k) clearance for use with bioMérieux VITEK® 2 Antimicrobial Susceptibility Testing System.

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Retrieved on: 
Thursday, January 25, 2024

Revenue was $11.3 million for the three months ended December 31, 2023, an increase of $4.1 million, or 58%, over the three months ended December 31, 2022.

Key Points: 
  • Revenue was $11.3 million for the three months ended December 31, 2023, an increase of $4.1 million, or 58%, over the three months ended December 31, 2022.
  • HF revenue units in the U.S. totaled 330 and 193 for the three months ended December 31, 2023 and 2022, respectively.
  • HF revenue in the U.S. totaled $10.2 million and $6.0 million for the three months ended December 31, 2023 and 2022, respectively.
  • As of December 31, 2023, the Company had a total of 178 active implanting centers, as compared to 159 as of September 30, 2023.

Palmetto Pharm Selects Inovalon ScriptMed® To Improve Patient Outcomes and Streamline Operations

Retrieved on: 
Monday, January 22, 2024

Inovalon’s ScriptMed Specialty will equip Palmetto Pharm with actionable insights to reduce administrative burden, foster improved collaboration between patients, providers, and health plans, and accelerate the time to therapies for enhanced clinical and financial outcomes.

Key Points: 
  • Inovalon’s ScriptMed Specialty will equip Palmetto Pharm with actionable insights to reduce administrative burden, foster improved collaboration between patients, providers, and health plans, and accelerate the time to therapies for enhanced clinical and financial outcomes.
  • Founded in 2022, Palmetto Pharm required a best-in-class cloud-based platform to scale efficiently and achieve its goal of becoming a nationwide specialty pharmacy licensed in all 50 states.
  • With their selection of the Inovalon pharmacy software platform solution, ScriptMed Specialty will now serve as the foundation for Palmetto Pharm’s customer-centric approach, which enables providers and patients to focus on managing their care for optimal outcomes.
  • Adopting best-in-class technology is just one way Palmetto Pharm goes the extra mile for patients and care teams, positioning them for continued success in the fast-growing specialty pharmacy market."

Alpha Modus Retains Christopher E. Hanba for the Purpose of Intellectual Property Rights Litigation

Retrieved on: 
Thursday, January 18, 2024

CORNELIUS, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Modus, Corp. (“Alpha Modus” or the “Company”), a technology company with a core focus on artificial intelligence in retail, is pleased to announce that the Company has retained the services of Christopher E. Hanba of Dickinson Wright PLLC, a leading global law firm, for his legal expertise, technical industry knowledge, and deep experience with enforcing intellectual property rights.

Key Points: 
  • Christopher Hanba has almost 20 years of experience in intellectual property litigation, particularly within the technology sector.
  • Mr. Hanba acts as lead counsel on patent, trademark, copyright, and trade secret misappropriation litigation matters.
  • In addition, he regularly appears before the federal courts and the International Trade Commission and is well-versed to efficiently manage litigation processes with demonstrable results.
  • Mr. Hanba is also known as a thought leader on evolving technology and the impact on intellectual property, including artificial intelligence.

ServiceNow Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Wednesday, January 24, 2024

See the section entitled “Statement Regarding Use of Non-GAAP Financial Measures” for an explanation of non-GAAP measures.

Key Points: 
  • See the section entitled “Statement Regarding Use of Non-GAAP Financial Measures” for an explanation of non-GAAP measures.
  • Refer to the table entitled “Reconciliation of Non-GAAP Financial Guidance” for a reconciliation of GAAP to non-GAAP measures.
  • We use the following non-GAAP financial measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.
  • We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current financial quarter.

TechTalk Summits' IMPACT 2024 Features AI Thought Leaders and Analysts

Retrieved on: 
Monday, January 29, 2024

BOSTON, Jan. 29, 2024 /PRNewswire/ -- TechTalk Summits' event, IMPACT 2024 will explore how businesses should adapt to and adopt machine learning technologies as they strive to integrate AI with business processes and human resources. The upcoming event is scheduled for Feb. 5-7, 2024, at The Vinoy Resort & Golf Club in St. Petersburg, FL.

Key Points: 
  • IMPACT 2024 provides strategic analysis in accessing resources, and technologies to develop an AI transformation plan.
  • BOSTON, Jan. 29, 2024 /PRNewswire/ -- TechTalk Summits' event, IMPACT 2024 will explore how businesses should adapt to and adopt machine learning technologies as they strive to integrate AI with business processes and human resources.
  • IMPACT 2024 features analysts and keynotes from TechTalk's strategic research partner, International Data Group (IDC), recently awarded Global Analyst Firm of the Year, four consecutive years running*.
  • IMPACT 2024 attendees will have access to sponsoring companies leading the way in ML applications, analysts through 1:1 briefings, as well as networking opportunities.

J.P. Morgan Wealth Plan Named #1 New Tool among Online Brokers

Retrieved on: 
Wednesday, January 24, 2024

J.P. Morgan Wealth Management’s Wealth Plan was named the #1 New Tool in StockBrokers.com’s 2024 Annual Awards , which recognize the best online brokerage and trading platforms.

Key Points: 
  • J.P. Morgan Wealth Management’s Wealth Plan was named the #1 New Tool in StockBrokers.com’s 2024 Annual Awards , which recognize the best online brokerage and trading platforms.
  • Wealth Plan is a free digital money coach that helps Chase customers, including those who invest on their own with J.P. Morgan Self-Directed Investing, plan, save and invest for their goals, all in one place.
  • Power recently named J.P. Morgan Wealth Management the #1 Digital Experience for Wealth Management Self-Directed Investor Satisfaction.
  • “We’re investing in strengthening Self-Directed Investing, and Wealth Plan is a key feature for our customers,” said Paul Vienick, Head of Online Investing at J.P. Morgan Wealth Management.

Reveal Announces Partnership with ModeOne to Integrate & Innovate Mobile Data Collection in eDiscovery

Retrieved on: 
Wednesday, January 24, 2024

The challenge facing many organizations is clear: a significant rise in eDiscovery cases involving mobile data, combined with escalating fines for inadequately managing messaging apps and personal devices.

Key Points: 
  • The challenge facing many organizations is clear: a significant rise in eDiscovery cases involving mobile data, combined with escalating fines for inadequately managing messaging apps and personal devices.
  • Reveal’s strategic partnership with ModeOne introduces an innovative, cost-efficient solution for the collection of data from personal and corporate-issued mobile devices.
  • “Mobile data is central to legal proceedings, our partnership with ModeOne is a strategic step towards ensuring that the collection and analysis of this essential data in the eDiscovery process is as seamless and efficient as possible,” said Wendell Jisa, founder & CEO of Reveal.
  • Reveal is committed to empowering its users with this unique and powerful data acquisition capability, marking a significant advancement in eDiscovery.

stackArmor’s ThreatAlert ATO® Accelerator Supports NIH AIM-AHEAD Program

Retrieved on: 
Tuesday, January 23, 2024

The AIM-AHEAD program mission is to enhance the participation of underrepresented communities in the development of AI/ML models.

Key Points: 
  • The AIM-AHEAD program mission is to enhance the participation of underrepresented communities in the development of AI/ML models.
  • A key infrastructure of the program, the AIM-AHEAD Service Workbench, is a FISMA Moderate ATO (Authority to Operate)-compliant self-service AI platform.
  • stackArmor’s ThreatAlert® ATO Accelerator enabled the workbench solution by providing an ATO-ready landing zone with NIST SP 800-53 compliant security services to meet specific NIH and Federal cybersecurity requirements.
  • To learn more about the NIH AIM AHEAD program, visit https://www.aim-ahead.net/ .